Theranos

Still Going for Small

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

The US Securities and Exchange Commission charged Elizabeth Holmes, the founder and CEO of Theranos, with fraud.

The Wall Street Journal reports that the erstwhile partners have reached a settlement of more than $25 million.

Asking for the Data

Biotech investors are learning from their mistakes following the Theranos fiasco, according to Wired.

Theranos Settles

The embattled firm has reached deals with both the Centers for Medicare & Medicaid Services and Arizona.

Elizabeth Holmes, the founder of Theranos, owes the firm millions, the Wall Street Journal reports.

'Repeated Violations'

A federal inspection report obtained by the Wall Street Journal describes deficiencies at Theranos' Arizona lab.

Second Failure

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

Pages

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.